Axon Enterprise, Inc. (NASDAQ:AXON) Shares Purchased by ProShare Advisors LLC

ProShare Advisors LLC increased its stake in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 965.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 96,998 shares of the biotechnology company's stock after buying an additional 87,898 shares during the quarter. ProShare Advisors LLC owned about 0.13% of Axon Enterprise worth $57,648,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of AXON. New Wave Wealth Advisors LLC acquired a new stake in shares of Axon Enterprise in the fourth quarter valued at about $40,000. Y.D. More Investments Ltd acquired a new stake in shares of Axon Enterprise in the fourth quarter valued at about $45,000. Stonebridge Financial Group LLC acquired a new stake in shares of Axon Enterprise in the fourth quarter valued at about $53,000. GPS Wealth Strategies Group LLC grew its stake in shares of Axon Enterprise by 74.1% in the fourth quarter. GPS Wealth Strategies Group LLC now owns 94 shares of the biotechnology company's stock valued at $56,000 after buying an additional 40 shares in the last quarter. Finally, Berbice Capital Management LLC acquired a new stake in shares of Axon Enterprise in the fourth quarter valued at about $59,000. Institutional investors and hedge funds own 79.08% of the company's stock.

Insider Buying and Selling

In related news, Director Jeri Williams sold 307 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $552.72, for a total value of $169,685.04. Following the sale, the director now owns 1,627 shares of the company's stock, valued at approximately $899,275.44. This trade represents a 15.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Brittany Bagley sold 3,400 shares of the firm's stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $700.00, for a total value of $2,380,000.00. Following the completion of the sale, the chief financial officer now owns 131,833 shares in the company, valued at approximately $92,283,100. This represents a 2.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 23,764 shares of company stock valued at $14,856,635. Insiders own 4.40% of the company's stock.

Axon Enterprise Stock Performance

NASDAQ:AXON traded up $4.79 during trading hours on Friday, reaching $733.18. 419,101 shares of the stock were exchanged, compared to its average volume of 759,084. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. The firm has a 50 day simple moving average of $584.61 and a 200-day simple moving average of $595.70. Axon Enterprise, Inc. has a 52 week low of $273.52 and a 52 week high of $735.68. The stock has a market capitalization of $57.08 billion, a P/E ratio of 189.45, a P/E/G ratio of 5.17 and a beta of 1.24.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.07. The business had revenue of $603.63 million for the quarter, compared to the consensus estimate of $585.67 million. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The business's revenue was up 31.3% on a year-over-year basis. During the same quarter last year, the business posted $1.15 EPS. As a group, sell-side analysts forecast that Axon Enterprise, Inc. will post 5.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have weighed in on AXON. The Goldman Sachs Group raised their price objective on Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a research note on Wednesday. Craig Hallum lowered Axon Enterprise from a "buy" rating to a "cautious" rating in a research note on Monday, March 10th. Needham & Company LLC raised their price objective on Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Northcoast Research lowered Axon Enterprise from a "buy" rating to a "neutral" rating in a research note on Wednesday, February 19th. Finally, JMP Securities restated an "outperform" rating on shares of Axon Enterprise in a research note on Tuesday, February 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company. According to MarketBeat, Axon Enterprise has an average rating of "Moderate Buy" and a consensus price target of $652.73.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.